In the US, incidence of essential thrombocythemia (ET) is reported to be 1.55 per 100,000 person-years (data from 2002 to 2016).[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
In the UK, annual incidence of ET is 4.2 per 100,000, with an estimated 2,720 people newly diagnosed each year (data from 2010 to 2019).[13]The Haematological Malignancy Research Network. Factsheets: essential thrombocythaemia 2022. Apr 2024 [internet publication].
https://hmrn.org/factsheets
ET occurs more commonly in females (male to female rate ratio approximately 0.8).[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
[13]The Haematological Malignancy Research Network. Factsheets: essential thrombocythaemia 2022. Apr 2024 [internet publication].
https://hmrn.org/factsheets
Incidence is highest among black people in the US.[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
ET more commonly affects older people (approximately 66% of patients in the US are age ≥60 years at diagnosis), but younger people may develop the disease.[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
Median age at diagnosis is 67 years in the US, and 72 years in the UK.[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
[13]The Haematological Malignancy Research Network. Factsheets: essential thrombocythaemia 2022. Apr 2024 [internet publication].
https://hmrn.org/factsheets
Prevalence in the general population is approximately 30 to 60 per 100,000.[14]Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006 Apr;32(3):171-3.
http://www.ncbi.nlm.nih.gov/pubmed/16673273?tool=bestpractice.com
[15]Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600.
http://www.ncbi.nlm.nih.gov/pubmed/23768070?tool=bestpractice.com
[16]Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008 May;83(5):359-62.
https://www.doi.org/10.1002/ajh.21129
http://www.ncbi.nlm.nih.gov/pubmed/18181200?tool=bestpractice.com
[17]Brière JB. Essential thrombocythemia. Orphanet J Rare Dis. 2007 Jan 8;2:3.
https://www.doi.org/10.1186/1750-1172-2-3
http://www.ncbi.nlm.nih.gov/pubmed/17210076?tool=bestpractice.com